United Therapeutics
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1996-01-01
- Employees
- -
- Market Cap
- $15.5B
- Website
- http://www.unither.com
Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH
- Conditions
- Interventions
- First Posted Date
- 2019-03-25
- Last Posted Date
- 2021-03-16
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 43
- Registration Number
- NCT03888365
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Beverly Hills, California, United States
🇺🇸The Mount Sinai Hospital, New York, New York, United States
🇺🇸Pulmonary Health Physicians, PC, Fayetteville, New York, United States
A Safety Study of IV Stem Cell-derived Extracellular Vesicles (UNEX-42) in Preterm Neonates at High Risk for BPD
- Conditions
- Interventions
- First Posted Date
- 2019-02-28
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 3
- Registration Number
- NCT03857841
- Locations
- 🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
- Conditions
- Interventions
- First Posted Date
- 2019-01-07
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 41
- Registration Number
- NCT03794583
- Locations
- 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸University of Illinois Medical Center, Chicago, Illinois, United States
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
- First Posted Date
- 2018-09-25
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 1000
- Registration Number
- NCT03683186
- Locations
- 🇺🇸
Baylor University Medical Center, Dallas, Texas, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸St. Joseph's Hospital and Medical Center-Norton Thoracic Institute, Phoenix, Arizona, United States
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
- First Posted Date
- 2018-08-13
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 1000
- Registration Number
- NCT03626688
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
🇺🇸Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension
- Conditions
- Interventions
- First Posted Date
- 2018-04-13
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 36
- Registration Number
- NCT03497689
- Locations
- 🇺🇸
UPMC Presbytarian Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸St. Vincent Medical Group, Indianapolis, Indiana, United States
🇺🇸University of Cincinnati Health, Cincinnati, Ohio, United States
A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2018-04-12
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 188
- Registration Number
- NCT03496623
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸Pulmonary & Critical Care of Atlanta, Atlanta, Georgia, United States
🇺🇸St. Vincent Medical Group, Inc., Indianapolis, Indiana, United States
Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-03-31
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 483
- Registration Number
- NCT03098030
- Locations
- 🇺🇸
Genesis Cancer Center, Hot Springs, Arkansas, United States
🇺🇸Hartford Hospital, Hartford, Connecticut, United States
🇭🇺Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Oktatókórház, Semmelweis Tagkórház, Tüdőgyógyászati Osztály, Miskolc, Hungary
TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH)
- Conditions
- Interventions
- First Posted Date
- 2017-02-16
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT03055221
Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Sickle Cell Disease (SCD)
- Conditions
- Interventions
- First Posted Date
- 2017-02-16
- Last Posted Date
- 2017-04-11
- Lead Sponsor
- United Therapeutics
- Registration Number
- NCT03055234